Agios Pharmaceuticals Inc... (AGIO)
| Bid | 30.99 |
| Market Cap | 1.85B |
| Revenue (ttm) | 36.81M |
| Net Income (ttm) | 679.52M |
| EPS (ttm) | 11.64 |
| PE Ratio (ttm) | 2.78 |
| Forward PE | -5.79 |
| Analyst | Buy |
| Ask | 33.93 |
| Volume | 325,060 |
| Avg. Volume (20D) | 746,963 |
| Open | 31.67 |
| Previous Close | 31.30 |
| Day's Range | 31.44 - 32.52 |
| 52-Week Range | 27.14 - 62.58 |
| Beta | 0.90 |
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Ph...
Analyst Forecast
According to 9 analyst ratings, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 69.96% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call TranscriptAgios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO C...
2 months ago · businesswire.com
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business OfficerBURLINGTON, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of car...